Table 2. Antimicrobial resistance (non-susceptible isolates) of Nocardia farcinica according to different series (n>100).
Amox-clav, amoxicillin-clavulanate; AMK, amikacin; CIP, ciprofloxacin; IMP, imipenem-cilastatin; Mino, minocycline; USA, United States of America; TMP-SMX, trimethoprim/sulfamethoxazole
| Country [ref.] | No. of isolates | TMP-SMX | IMP | AMK | Linezolid | Mino | Amox-clav | Cefotaxime | Ceftriaxone | CIP |
| Spain [1] | 128 | 45.3% | 3.9% | 1.6% | 3.1% | 89.1% | 18% | 54.7% | - | 48.4% |
| France [17] | 149 | 4% | 23% | 1.4% | 0% | 12.8% | 20.1% | 79.7% | 80.5% | 41.9% |
| USA [18] | 105 | 80% | 25% | 0% | 0% | 79% | 10% | 93% | 72% | |
| USA [19] | 319 | 1% | 17% | 0% | 0% | 93% | 4% | - | 97% | 51% |